Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | QPCT | Q16769 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13609136 | 0.91 | GAA (0.61) | GAATSHRALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL14271650 | 0.87 | ALDH1A1 (0.50) | GAAALDH1A1NPC1SMN1; SMN2MEN1 | |
| SCHEMBL10311722 | 0.84 | QPCT (0.50) | ALDH1A1NPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL291623 | 0.83 | USP2 (0.59) | GAAUSP2NPC1SMN1; SMN2MEN1 | |
| SCHEMBL3706925 | 0.82 | QPCT (0.43) | ALDH1A1NPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL10448593 | 0.82 | QPCT (0.43) | ALDH1A1NPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15014468 | 0.80 | KDM4E (0.55) | GAAALDH1A1NPC1SMN1; SMN2MEN1 | |
| SCHEMBL4399230 | 0.79 | ALDH1A1 (0.54) | ALDH1A1NPC1SMN1; SMN2QPCTL3MBTL1 | |
| SCHEMBL3051649 | 0.77 | EGLN3 (0.59) | ALDH1A1NPC1SMN1; SMN2QPCTL3MBTL1 | |
| SCHEMBL12424659 | 0.77 | MEN1 (0.57) | GAAALDH1A1NPC1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291923-A1 | TRIOXANE DIMERS HAVING HIGH ANTICANCER AND LONG-LASTING ANTIMALARIAL ACTIVITIES | JOHNS HOPKINS UNIVERSOTY (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291923-A1 | TRIOXANE DIMERS HAVING HIGH ANTICANCER AND LONG-LASTING ANTIMALARIAL ACTIVITIES | HCCS, XPO5, DHX15 | GAA 3851/4885USP2 3462/4885TSHR 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.